|
1
|
Bertuccio P, Chatenoud L, Levi F, et al:
Recent patterns in gastric cancer: a global overview. Int J Cancer.
125:666–673. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar
|
|
3
|
Macdonald JS, Smalley SR, Benedetti J, et
al: Chemoradiotherapy after surgery compared with surgery alone for
adenocarcinoma of the stomach or gastroesophageal junction. N Engl
J Med. 345:725–730. 2001. View Article : Google Scholar
|
|
4
|
Cunningham D, Allum WH, Stenning SP, et
al: Perioperative chemotherapy versus surgery alone for resectable
gastroesophageal cancer. N Engl J Med. 355:11–20. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Scartozzi M, Galizia E, Verdecchia L, et
al: Chemotherapy for advanced gastric cancer: across the years for
a standard of care. Expert Opin Pharmacother. 8:797–808.
2007.PubMed/NCBI
|
|
6
|
Wagner AD, Grothe W, Haerting J, Kleber G,
Grothey A and Fleig WE: Chemotherapy in advanced gastric cancer: a
systematic review and meta-analysis based on aggregate data. J Clin
Oncol. 24:2903–2909. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Emadi A and Gore SD: Arsenic trioxide - an
old drug rediscovered. Blood Rev. 24:191–199. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Douer D and Tallman MS: Arsenic trioxide:
new clinical experience with an old medication in hematologic
malignancies. J Clin Oncol. 23:2396–2410. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chen Z, Chen GQ, Shen ZX, et al: Expanding
the use of arsenic trioxide: leukemias and beyond. Semin Hematol.
39(Suppl 1): S22–S26. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sekeres MA: New data with arsenic trioxide
in leukemias and myelodysplastic syndromes. Clin Lymphoma Myeloma.
8(Suppl 1): S7–S12. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zheng Y, Zhou M, Ye A, Li Q, Bai Y and
Zhang Q: The conformation change of Bcl-2 is involved in arsenic
trioxide-induced apoptosis and inhibition of proliferation in
SGC7901 human gastric cancer cells. World J Surg Oncol. 8:312010.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Fei M, Lu M, Wang Y, et al: Arsenic
trioxide-induced growth arrest of human hepatocellular carcinoma
cells involving FOXO3a expression and localization. Med Oncol.
26:178–185. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chow SK, Chan JY and Fung KP: Inhibition
of cell proliferation and the action mechanisms of arsenic trioxide
(As2O3) on human breast cancer cells. J Cell
Biochem. 93:173–187. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Qu GP, Xiu QY, Li B, Liu YA and Zhang LZ:
Arsenic trioxide inhibits the growth of human lung cancer cell
lines via cell cycle arrest and induction of apoptosis at both
normoxia and hypoxia. Toxicol Ind Health. 25:505–515. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Karlsson J, Pietras A, Beckman S,
Pettersson HM, Larsson C and Påhlman S: Arsenic trioxide-induced
neuroblastoma cell death is accompanied by proteolytic activation
of nuclear Bax. Oncogene. 26:6150–6159. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Park WH, Cho YH, Jung CW, et al: Arsenic
trioxide inhibits the growth of A498 renal cell carcinoma cells via
cell cycle arrest or apoptosis. Biochem Biophys Res Commun.
300:230–235. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kanzawa T, Kondo Y, Ito H, Kondo S and
Germano I: Induction of autophagic cell death in malignant glioma
cells by arsenic trioxide. Cancer Res. 63:2103–2108.
2003.PubMed/NCBI
|
|
18
|
Altman JK, Yoon P, Katsoulidis E, et al:
Regulatory effects of mammalian target of rapamycin-mediated
signals in the generation of arsenic trioxide responses. J Biol
Chem. 283:1992–2001. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Miller WH Jr, Schipper HM, Lee JS, Singer
J and Waxman S: Mechanisms of action of arsenic trioxide. Cancer
Res. 62:3893–3903. 2002.PubMed/NCBI
|
|
20
|
Zhou J: Arsenic trioxide: an ancient drug
revived. Chin Med J. 125:3556–3560. 2012.PubMed/NCBI
|
|
21
|
Mandegary A, Hosseini R, Ghaffari SH, et
al: The expression of p38, ERK1 and Bax proteins has increased
during the treatment of newly diagnosed acute promyelocytic
leukemia with arsenic trioxide. Ann Oncol. 21:1884–1890. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zheng Y, Yamaguchi H, Tian C, et al:
Arsenic trioxide (As2O3) induces apoptosis
through activation of Bax in hematopoietic cells. Oncogene.
24:3339–3347. 2005.PubMed/NCBI
|
|
23
|
Scholz C, Richter A, Lehmann M,
Schulze-Osthoff K, Dörken B and Daniel PT: Arsenic trioxide induces
regulated, death receptor-independent cell death through a
Bcl-2-controlled pathway. Oncogene. 24:7031–7042. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Li Y, Qu X, Qu J, et al: Arsenic trioxide
induces apoptosis and G2/M phase arrest by inducing Cbl to inhibit
PI3K/Akt signaling and thereby regulate p53 activation. Cancer
Lett. 284:208–215. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Han YH, Kim SZ, Kim SH and Park WH:
Arsenic trioxide inhibits the growth of Calu-6 cells via inducing a
G2 arrest of the cell cycle and apoptosis accompanied with the
depletion of GSH. Cancer Lett. 270:40–55. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhao S, Zhang J, Zhang X, Dong X and Sun
X: Arsenic trioxide induces different gene expression profiles of
genes related to growth and apoptosis in glioma cells dependent on
the p53 status. Mol Biol Rep. 35:421–429. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Jarpe MB, Widmann C, Knall C, et al:
Anti-apoptotic versus pro-apoptotic signal transduction:
checkpoints and stop signs along the road to death. Oncogene.
17:1475–1482. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Franke TF, Hornik CP, Segev L, Shostak GA
and Sugimoto C: PI3K/Akt and apoptosis: size matters. Oncogene.
22:8983–8998. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Bader AG, Kang S, Zhao L and Vogt PK:
Oncogenic PI3K deregulates transcription and translation. Nat Rev
Cancer. 5:921–929. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Niedermeier M, Hennessy BT, Knight ZA, et
al: Isoform-selective phosphoinositide 3′-kinase inhibitors inhibit
CXCR4 signaling and overcome stromal cell-mediated drug resistance
in chronic lymphocytic leukemia: a novel therapeutic approach.
Blood. 113:5549–5557. 2009.
|
|
31
|
Garcia-Echeverria C and Sellers WR: Drug
discovery approaches targeting the PI3K/Akt pathway in cancer.
Oncogene. 27:5511–5526. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Redondo-Muñoz J, Escobar-Díaz E, Hernández
Del Cerro M, et al: Induction of B-chronic lymphocytic leukemia
cell apoptosis by arsenic trioxide involves suppression of the
phosphoinositide 3-kinase/Akt survival pathway via
c-jun-NH2 terminal kinase activation and PTEN
upregulation. Clin Cancer Res. 16:4382–4391. 2010.PubMed/NCBI
|
|
33
|
Choi YJ, Park JW, Suh SI, et al: Arsenic
trioxide-induced apoptosis in U937 cells involve generation of
reactive oxygen species and inhibition of Akt. Int J Oncol.
21:603–610. 2002.PubMed/NCBI
|
|
34
|
Tabellini G, Tazzari PL, Bortul R, et al:
Phosphoinositide 3-kinase/Akt inhibition increases arsenic
trioxide-induced apoptosis of acute promyelocytic and T-cell
leukaemias. Br J Haematol. 130:716–725. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Tabellini G, Cappellini A, Tazzari PL, et
al: Phosphoinositide 3-kinase/Akt involvement in arsenic trioxide
resistance of human leukemia cells. J Cell Physiol. 202:623–634.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ramos AM, Fernández C, Amrán D, Sancho P,
de Blas E and Aller P: Pharmacologic inhibitors of PI3K/Akt
potentiate the apoptotic action of the antileukemic drug arsenic
trioxide via glutathione depletion and increased peroxide
accumulation in myeloid leukemia cells. Blood. 105:4013–4020. 2005.
View Article : Google Scholar
|
|
37
|
Dougherty CJ, Kubasiak LA, Prentice H,
Andreka P, Bishopric NH and Webster KA: Activation of c-Jun
N-terminal kinase promotes survival of cardiac myocytes after
oxidative stress. Biochem J. 362:561–571. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Shen ZX, Chen GQ, Ni JH, et al: Use of
arsenic trioxide (As2O3) in the treatment of
acute promyelocytic leukemia (APL): II. Clinical efficacy and
pharmacokinetics in relapsed patients. Blood. 89:3354–3360.
1997.PubMed/NCBI
|
|
39
|
Jiang X, Chen C, Zhao W and Zhang Z:
Sodium arsenite and arsenic trioxide differently affect the
oxidative stress, genotoxicity and apoptosis in A549 cells: an
implication for the paradoxical mechanism. Environ Toxicol
Pharmacol. 36:891–902. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Liu B, Pan S, Dong X, et al: Opposing
effects of arsenic trioxide on hepatocellular carcinomas in mice.
Cancer Sci. 97:675–681. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Hoffman E and Mielicki WP: Arsenic
trioxide: impact on the growth and differentiation of cancer cells
and possible use in cancer therapy. Postepy Hig Med Dosw.
67:817–827. 2013.(In Polish).
|
|
42
|
Xiao YF, Liu SX, Wu DD, Chen X and Ren LF:
Inhibitory effect of arsenic trioxide on angiogenesis and
expression of vascular endothelial growth factor in gastric cancer.
World J Gastroenterol. 12:5780–5786. 2006.PubMed/NCBI
|
|
43
|
Shao QS, Ye ZY, Ling ZQ and Ke JJ: Cell
cycle arrest and apoptotic cell death in cultured human gastric
carcinoma cells mediated by arsenic trioxide. World J
Gastroenterol. 11:3451–3456. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Hayashi T, Hideshima T, Akiyama M, et al:
Arsenic trioxide inhibits growth of human multiple myeloma cells in
the bone marrow microenvironment. Mol Cancer Ther. 1:851–860.
2002.PubMed/NCBI
|
|
45
|
Baj G, Arnulfo A, Deaglio S, et al:
Arsenic trioxide and breast cancer: analysis of the apoptotic,
differentiative and immunomodulatory effects. Breast Cancer Res
Treat. 73:61–73. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Wu DD, Xiao YF, Geng Y and Hou J:
Antitumor effect and mechanisms of arsenic trioxide on
subcutaneously implanted human gastric cancer in nude mice. Cancer
Genet Cytogenet. 198:90–96. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Soucy NV, Ihnat MA, Kamat CD, et al:
Arsenic stimulates angiogenesis and tumorigenesis in vivo. Toxicol
Sci. 76:271–279. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Wu YC, Yen WY and Yih LH: Requirement of a
functional spindle checkpoint for arsenite-induced apoptosis. J
Cell Biochem. 105:678–687. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Zhao S, Tsuchida T, Kawakami K, Shi C and
Kawamoto K: Effect of As2O3 on cell cycle
progression and cyclins D1 and B1 expression in two glioblastoma
cell lines differing in p53 status. Int J Oncol. 21:49–55.
2002.
|
|
50
|
Zhang X, Jia S, Yang S and Yang Y, Yang T
and Yang Y: Arsenic trioxide induces G2/M arrest in hepatocellular
carcinoma cells by increasing the tumor suppressor PTEN expression.
J Cell Biochem. 113:3528–3535. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Zhang Y, Cao EH and Qin JF: Up-regulation
of telomere-binding TRF1, TRF2 related to reactive oxygen species
induced by As2O3 in MGC-803 cells. Eur J
Pharmacol. 516:1–9. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Jiang XH, Wong BC, Yuen ST, et al: Arsenic
trioxide induces apoptosis in human gastric cancer cells through
up-regulation of p53 and activation of caspase-3. Int J Cancer.
91:173–179. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Baysan A, Yel L, Gollapudi S, Su H and
Gupta S: Arsenic trioxide induces apoptosis via the mitochondrial
pathway by upregulating the expression of Bax and Bim in human B
cells. Int J Oncol. 30:313–318. 2007.PubMed/NCBI
|
|
54
|
Paul MK, Kumar R and Mukhopadhyay AK:
Dithiothreitol abrogates the effect of arsenic trioxide on normal
rat liver mitochondria and human hepatocellular carcinoma cells.
Toxicol Appl Pharmacol. 226:140–152. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Shen ZY, Shen J, Cai WJ, Hong C and Zheng
MH: The alteration of mitochondria is an early event of arsenic
trioxide-induced apoptosis in esophageal carcinoma cells. Int J Mol
Med. 5:155–158. 2000.PubMed/NCBI
|
|
56
|
Shen ZY, Shen J, Li QS, Chen CY, Chen JY
and Yi Z: Morphological and functional changes of mitochondria in
apoptotic esophageal carcinoma cells induced by arsenic trioxide.
World J Gastroenterol. 8:31–35. 2002.PubMed/NCBI
|
|
57
|
Zhou J, Ye J, Zhao X and Li A: JWA is
required for arsenic trioxide induced apoptosis in HeLa and MCF-7
cells via reactive oxygen species and mitochondria linked signal
pathway. Toxicol Appl Pharmacol. 230:33–40. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Selvaraj V, Armistead MY, Cohenford M and
Murray E: Arsenic trioxide (As2O3) induces
apoptosis and necrosis-mediated cell death through mitochondrial
membrane potential damage and elevated production of reactive
oxygen species in PLHC-1 fish cell line. Chemosphere. 90:1201–1209.
2013.PubMed/NCBI
|
|
59
|
Nutt LK, Gogvadze V, Uthaisang W,
Mirnikjoo B, McConkey DJ and Orrenius S: Indirect effects of Bax
and Bak initiate the mitochondrial alterations that lead to
cytochrome c release during arsenic trioxide-induced
apoptosis. Cancer Biol Ther. 4:459–467. 2005.PubMed/NCBI
|
|
60
|
Zheng Y, Shi Y, Tian C, et al: Essential
role of the voltage-dependent anion channel (VDAC) in mitochondrial
permeability transition pore opening and cytochrome c
release induced by arsenic trioxide. Oncogene. 23:1239–1247. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Uren RT, Dewson G, Chen L, et al:
Mitochondrial permeabilization relies on BH3 ligands engaging
multiple prosurvival Bcl-2 relatives, not Bak. J Cell Biol.
177:277–287. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Chen M, Guerrero AD, Huang L, et al:
Caspase-9-induced mitochondrial disruption through cleavage of
anti-apoptotic BCL-2 family members. J Biol Chem. 282:33888–33895.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Crowder RJ and Freeman RS: Glycogen
synthase kinase-3β activity is critical for neuronal death caused
by inhibiting phosphatidylinositol 3-kinase or Akt but not for
death caused by nerve growth factor withdrawal. J Biol Chem.
275:34266–34271. 2000.
|
|
64
|
Szanto A, Bognar Z, Szigeti A, Szabo A,
Farkas L and Gallyas F Jr: Critical role of bad phosphorylation by
Akt in cytostatic resistance of human bladder cancer cells.
Anticancer Res. 29:159–164. 2009.PubMed/NCBI
|
|
65
|
Cardone MH, Roy N, Stennicke HR, et al:
Regulation of cell death protease caspase-9 by phosphorylation.
Science. 282:1318–1321. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Chiu HW, Ho SY, Guo HR and Wang YJ:
Combination treatment with arsenic trioxide and irradiation
enhances autophagic effects in U118-MG cells through increased
mitotic arrest and regulation of PI3K/Akt and ERK1/2 signaling
pathways. Autophagy. 5:472–483. 2009. View Article : Google Scholar
|
|
67
|
Qian W, Liu J, Jin J, Ni W and Xu W:
Arsenic trioxide induces not only apoptosis but also autophagic
cell death in leukemia cell lines via up-regulation of Beclin-1.
Leuk Res. 31:329–339. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Mann KK, Colombo M and Miller WH Jr:
Arsenic trioxide decreases AKT protein in a caspase-dependent
manner. Mol Cancer Ther. 7:1680–1687. 2008. View Article : Google Scholar : PubMed/NCBI
|
